Margetuximab, when assessed in combination with pembrolizumab in a phase Ib/II trial of 92 response-evaluable patients with HER2-positive gastric or GOJ cancers previously treated with trastuzumab, demonstrated preliminary anti-tumour activity with an ORR of 18% and a tolerable safety profile [71]. This evidence concerns the gene ERBB2 and neoplasm.